{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-003781","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2024-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.742539+00:00","generated_at":"2026-06-06T05:48:12.581499+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Foghorn announces Lilly selects FHD-909 for clinical development; IND planned for Q2 2024","bullets":["Lilly selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development.","Lilly plans to file an IND for FHD-909 in Q2 2024 for BRG1 mutated NSCLC.","FHD-909 targets BRG1 mutant non-small cell lung cancer, exploiting BRM dependency.","Collaboration with Lilly announced Dec 2021 includes US 50/50 co-development and co-commercialization.","Foghorn and Lilly plan to present preclinical data at upcoming scientific conferences."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-003781","json":"https://secwatch.observer/filing/0001628280-24-003781.json","markdown":"https://secwatch.observer/filing/0001628280-24-003781.md","text":"https://secwatch.observer/filing/0001628280-24-003781.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024003781/0001628280-24-003781-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024003781/fhtx-20240208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T05:48:12.581499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}